Myovant Sciences Operating Margin 2017-2022 | MYOV

Current and historical operating margin for Myovant Sciences (MYOV) over the last 10 years. The current operating profit margin for Myovant Sciences as of March 31, 2022 is -89.18%.
Myovant Sciences Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2022-03-31 $0.23B $-0.19B -80.95%
2021-12-31 $0.20B $-0.21B -107.07%
2021-09-30 $0.15B $-0.23B -158.62%
2021-03-31 $0.06B $-0.26B -442.37%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.236B $0.231B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00